GrayBella Capital

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

Omnio Group, founded in 2018 and headquartered in London, is a provider of banking-as-a-Service solutions designed for banks, building societies, credit unions, and various corporate clients. The company specializes in digital banking, managed services, and digital payment solutions, enabling its clients to offer innovative and reliable financial services. Omnio's platform incorporates features such as loyalty programs and back-office services, allowing clients to enhance their product offerings and generate new revenue streams through embedded financial services. With a presence in Europe, Australia, North America, and Africa, Omnio supports over 130 small financial institutions and collaborates with leading businesses and government organizations to deliver effective financial products tailored to meet evolving customer needs.